2019
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Esteghamat F, Broughton JS, Smith E, Cardone R, Tyagi T, Guerra M, Szabó A, Ugwu N, Mani MV, Azari B, Kayingo G, Chung S, Fathzadeh M, Weiss E, Bender J, Mane S, Lifton RP, Adeniran A, Nathanson MH, Gorelick FS, Hwa J, Sahin-Tóth M, Belfort-DeAguiar R, Kibbey RG, Mani A. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nature Genetics 2019, 51: 1233-1243. PMID: 31358993, PMCID: PMC6675645, DOI: 10.1038/s41588-019-0470-3.Peer-Reviewed Original ResearchConceptsEarly-onset atherosclerosisMetabolic syndromeMetabolic syndrome traitsWhole-exome sequence analysisAttractive therapeutic targetPlatelet hyperactivationInsulin levelsPlasma insulinPlasma levelsInsulin sensitivityInsulin secretionTherapeutic targetPlatelet activationDisease mechanismsSyndrome traitsAtherosclerosisFunction mutationsSyndromeNovel lossInsulinMutationsSecretion
2014
Plasma Cardiotrophin‐1 Levels are Associated With Hypertensive Heart Disease: A Meta‐Analysis
Song K, Wang S, Huang B, Luciano A, Srivastava R, Mani A. Plasma Cardiotrophin‐1 Levels are Associated With Hypertensive Heart Disease: A Meta‐Analysis. Journal Of Clinical Hypertension 2014, 16: 686-692. PMID: 25052897, PMCID: PMC4159421, DOI: 10.1111/jch.12376.Peer-Reviewed Original ResearchConceptsCT-1 levelsPlasma CT-1 levelsHypertensive heart diseaseHeart failureLeft ventricular hypertrophyVentricular hypertrophyCardiotrophin-1Hypertensive patientsHeart diseaseHypertension-induced left ventricular hypertrophyCardiotrophin-1 levelsSmall independent studiesHypertension-induced hypertrophyInterleukin-6 cytokineNormotensive patientsSerum levelsSubgroup analysisCardiac hypertrophyNovel biomarkersHypertensionPatientsElectronic databasesHypertrophyMeta-AnalysisStandardized algorithm